Gastric cancer is the fifth most common cancer, with around one million annual incidences worldwide, and it represents the fourth most common cause of cancer deaths. High incidences of the disease in Asia mean that screening in countries like Japan have made survival rates better than in Western countries, where the disease is often already advanced by the time of diagnosis. The gastric cancer drug market is growing rapidly and is expected to approach USD 4 billion by 2029 according to GlobalData. Carl Bjartmar at Ascelia Pharma analyses why this growth, is fuelled by several factors, including an increase in the overall incidence, as well as higher treatment rates and extended treatment duration.